March 2026 Research Update

What became clearer this month

Studies this month add detail to a practical message: newborn screening and follow-up testing for CAH can be improved with more specific hormone measurements, but screening is still not perfect and coverage varies by region. A large newborn study found that confirmatory blood testing using LC-MS/MS (a more specific lab method) separated true CAH from false alarms better than an older immunoassay approach. Other reports show that some regions are expanding screening programs, while individual cases remind us that false-negative screens can still happen. [1] [2] [3] [4]

In a cohort of 708,437 newborns, serum 17-hydroxyprogesterone (17-OHP) measured by LC-MS/MS had a higher positive predictive value than 17-OHP measured by radioimmunoassay (49% vs 30%), meaning fewer babies flagged by screening were ultimately found not to have CAH. The same study reported that certain steroid ratios and adding genetic testing (CYP21A2) helped clarify indeterminate cases, which is relevant because newborn screening is meant to trigger quick, accurate follow-up rather than serve as a final diagnosis. [1]

Efforts to strengthen the lab side of CAH testing were also reflected in a report describing a candidate reference method for measuring 17-OHP in blood with low bias and good precision across a wide range. This kind of work matters because more consistent measurements across laboratories can make follow-up test results easier to compare and interpret over time, although this paper focused on the lab method itself rather than patient outcomes. [5]

Newborn screening availability and performance were highlighted in two different ways. One hospital-based screening program in Pune, India identified 4 newborns with CAH among 8007 screened and reported that these infants were treated and followed. A separate survey across 16 Southeastern and Central European countries described ongoing expansion plans that commonly included CAH, while noting barriers like funding and staffing and a lack of region-wide measures such as age at treatment start. [2] [3]

A single case report showed how CAH can still be missed by screening: a preterm infant with classic CAH had four negative newborn screens and was only diagnosed later after developing low sodium and high potassium and then having very high 17-OHP and confirmatory genetic testing. This illustrates that screening reduces risk but does not eliminate it, especially in specific situations not fully explained by this one case. [4]

What this means for patients and caregivers

This month mainly adds understanding about how CAH is detected early and how follow-up testing can be made more accurate. The strongest human evidence here suggests that when a newborn screen is abnormal, confirmatory blood tests using more specific measurement methods can reduce confusion from false positives, and genetic testing can help when results are unclear. At the same time, the case report of repeated negative screens shows that newborn screening is not a guarantee, and the survey work shows that screening access and program details still differ by country. These findings inform expectations about screening and testing systems, rather than changing day-to-day care for a person already diagnosed. [1] [4] [3] [2] [5]

What became clearer this month

Several studies this month focused on what long-term CAH can look like beyond hormone numbers, including growth patterns in childhood and quality of life in adulthood. The shared picture is that outcomes are shaped by age and by how treatment balances hormone control with side effects. These studies do not point to one single approach, but they make it clearer where challenges often show up: early weight rebound and growth changes in childhood, and lower reported quality of life in adults, especially in certain subgroups. [6] [7]

In a large international registry of 573 young people with 21-hydroxylase deficiency, adiposity rebound (the age when body weight starts rising again after early childhood) happened before age 5 in 82% of patients. The study also reported that higher glucocorticoid doses were linked with earlier adiposity rebound and heavier adolescent weight in girls, and with more advanced bone maturation in both sexes, which helps explain why growth and weight can be difficult to balance over time. [6]

A separate survey study of 362 responses compared adults with classical CAH to caregivers reporting on children with CAH and found that adults reported lower CAH-specific quality of life than children (mean 58.1 vs 73.5). In adults, worse scores were reported more often with older age, female sex, and public insurance, while CARES Center of Excellence affiliation and hydrocortisone use were linked to better scores in some areas; this helps clarify that the adult experience can differ substantially across life circumstances. [7]

One paper addressed how care is managed across life stages by describing challenges in transitioning from pediatric to adult endocrine care and offering practical strategies. Because it is a guidance document rather than new patient outcome data, it mainly signals that transition is a recognized pressure point and that adult care teams may face unfamiliar issues when caring for childhood-onset endocrine conditions like CAH. [8]

What this means for patients and caregivers

This month adds context for what families often notice over years: growth, weight, and well-being can shift with age and with treatment intensity. The registry data helps clarify that early childhood weight patterns and bone maturation are common areas to watch in research, and that higher glucocorticoid dosing was linked to earlier weight rebound and more advanced bone age in this dataset. The quality-of-life survey highlights that many adults report more day-to-day burden than children, and that social factors like insurance type were linked to differences in reported well-being, although surveys cannot prove what causes those differences. None of these studies by themselves dictate individual decisions, but together they explain why long-term follow-up research focuses not only on hormones, but also on growth, weight, mental well-being, and the transition into adult care. [6] [7] [8]

What became clearer this month

This month included a mix of real-world treatment adjustments, reports on access to newer glucocorticoid options, and surgical outcome studies related to genital reconstruction in CAH. The overall pattern is practical rather than definitive: some approaches showed improvements in targeted outcomes (like adrenal androgen control, symptoms of androgen deficiency, or postoperative function), but evidence often came from retrospective data or case reports. Another clear message is that availability and uptake of newer glucocorticoid formulations remain limited in many settings. [9] [10] [11] [12] [13] [14]

For adolescents with classic CAH who were inadequately controlled on hydrocortisone near final height, a retrospective study of 32 patients reported that switching to dexamethasone lowered adrenal androgens over 6 to 12 months. The same report described pubertal and gonadal changes in many patients, such as improved menstrual regularity in some female-reared patients and improved hormone patterns in male-reared patients, while also noting side effects including weight gain and Cushingoid features in some and red-purple stretch marks in 11 patients. [9]

Access to newer glucocorticoid products was addressed in an international registry analysis covering 2017 to 2023. Only 44 of 790 patients (about 5%) switched to modern glucocorticoids (Acecort, Alkindi, Efmody, or Plenadren), and availability differed by center, with barriers including regulatory approval, supply, and cost. This helps explain why many patients may not encounter these options even if they are discussed in CAH communities. [10]

Two reports focused on feminizing genital surgery outcomes. A multicenter study of 37 patients who had clitoroplasty with corporoplasty found preserved tactile sensitivity on standardized testing and cosmetic ratings that were generally good or satisfactory, with earlier age at surgery linked to better tactile sensitivity. A separate adult case report described successful reconstruction for persistent urogenital sinus, with normal urination and menstruation and preserved clitoral sensation at 3 months. [11] [12]

Several individual cases illustrated treatment decisions for less common or complex situations that can overlap with the broader CAH umbrella. One long follow-up case described a woman with salt-wasting CAH and symptoms linked to very low adrenal androgens during long-term glucocorticoid overtreatment, who reported sustained improvement after low-dose testosterone replacement without virilization over 10 years. Another case described a woman with 21-hydroxylase deficiency who presented with kidney dysfunction and polycythemia and improved after erythrocytapheresis and glucocorticoid adjustment, with worsening during a brief prednisone trial and improvement after returning to dexamethasone. [13] [14]

What this means for patients and caregivers

This month offers real-world examples of how CAH management can involve tradeoffs between symptom control and side effects, and how care can extend beyond hormones to areas like surgery and long-term well-being. The dexamethasone switch study suggests that stronger glucocorticoid regimens may lower adrenal androgens for some adolescents, while also reporting weight-related and Cushingoid side effects in some people, so the net experience can be mixed. The registry analysis on modern glucocorticoids clarifies that limited access and system barriers still strongly shape what treatments people actually receive. The surgery studies and case reports mainly add reassurance that some individuals had preserved sensation and functional outcomes after specific reconstructive approaches, while also underlining that these reports are based on cross-sectional data or small numbers and do not predict any one person outcome. [9] [10] [11] [12] [13] [14]

What became clearer this month

A set of studies this month broadened the CAH landscape by describing genetic causes of adrenal steroid disorders and possible body-wide effects, especially brain structure. The combined message is that genetics continues to clarify diagnosis in rarer forms of CAH-like conditions, and researchers are also trying to map long-term biological differences that may relate to lifelong hormone differences and treatment exposure. These findings are more about understanding than about immediate clinical change. [15] [16] [17]

In 113 genetically confirmed Chinese patients with complete 17alpha-hydroxylase/17,20-lyase deficiency (17-OHD), researchers identified 50 pathogenic CYP17A1 variants including 6 novel mutations and found that most variants caused near-complete loss of enzyme activity in lab testing. The study also described a common founder hotspot in this population, which can matter for genetic testing strategies and family counseling in regions where that variant is frequent. [15]

A multicenter Brazilian study of 12 unrelated families with X-linked congenital adrenal hypoplasia reported a wide range of NR0B1 variants, including deletions and truncating variants, alongside early adrenal insufficiency and frequent puberty-related hypogonadism and infertility. While not CAH due to 21-hydroxylase deficiency, it is part of the broader group of inherited adrenal conditions that can look similar early on and later affect puberty and fertility. [16]

A brain imaging study compared 53 adults with classic CAH with 53 matched controls and found widespread thinning of the outer brain layer (cortical thinning) across many regions in CAH, with no differences by sex. This does not show what causes the difference, but it supports the idea that lifelong differences in cortisol exposure, treatment, and stress biology could be linked to measurable brain structure differences that deserve further study. [17]

What this means for patients and caregivers

These studies mainly matter for understanding and diagnosis, especially for families affected by rarer inherited adrenal steroid disorders. The genetic studies show that specific gene changes can be mapped and tested, and that some variants may be common in certain populations, which can speed recognition of the underlying condition. The brain imaging findings add to research suggesting that classic CAH may be linked with long-term differences in the brain, but they do not tell us how this affects thinking, mood, or daily function in any one person. Taken together, this month strengthens the idea that CAH and related disorders are not only about early-life symptoms, and that genetics and long-term biology research are expanding what can be studied in the future. [15] [16] [17]

What became clearer this month

This month included small reports about sex development and fertility that show how varied these experiences can be across different adrenal steroid disorders. A small series of 46,XX people with very severe virilization raised as male mostly reported stable male gender identity, while a separate case report described two sisters with a different condition (POR deficiency) who achieved live births through IVF. These reports add examples and long-term observations, but they do not provide predictable probabilities for other families. [18] [19]

A case series from one center described 4 severely virilized 46,XX individuals with CAH who were assigned and raised as male and maintained a stable male gender identity. The authors also summarized published cases where outcome information was available, reporting that most maintained a male gender identity, while a smaller number experienced gender reassignment or psychological difficulties. [18]

In two sisters with 46,XX nonclassic POR deficiency, both achieved singleton live births using IVF with a freeze-all strategy followed by frozen embryo transfer with hormone support and glucocorticoids. The report also identified a novel POR gene variant in this family, expanding what is known about genetic causes of this condition in Chinese populations. [19]

What this means for patients and caregivers

For families facing questions about sex development, gender identity, or fertility, these reports mainly add lived examples rather than general answers. The 46,XX CAH case series plus literature summary suggests that stable male gender identity is common among people with very severe virilization who were raised as male, while also acknowledging that psychological distress and reassignment have been reported in some cases. The POR deficiency fertility report shows that pregnancy can be possible in some individuals with rarer steroid disorders using assisted reproduction, but it remains based on a very small number of people and does not indicate how often this will work for others. [18] [19]